Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UHE-103 Cream vs Naftin in Tinea Cruris/Pedis
NCT05363449Phase 1Completed
- Start
- Feb 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of UHE-103 in Tinea cruris (TC) and tinea pedis (2 arms). Primary endpoints: Adverse Events (AEs) at Day 16, Local Skin Reactions (LSRs) at Day 16 and 1 more. Started Feb 2022; status: completed.
02
Drugs
UHE-103
03
Conditions
Tinea cruris (TC)tinea pedis
Beyond the preview
Go deeper on NCT05363449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05363449.